Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Toxicokinetics: Overview01:21

Toxicokinetics: Overview

Studies that assess how a drug is absorbed, distributed, metabolized, and excreted (ADME) at toxic doses are termed toxicokinetics. Understanding toxicokinetics helps predict adverse drug reactions (ADRs) and manage toxicity in humans.Toxicokinetics differs from pharmacokinetics mainly in the dose levels studied, with toxicokinetics focusing on higher toxic doses. The kinetics at these levels can be non-linear due to altered physiological processes. Toxicodynamics examines the relationship...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preclinical imaging methods for assessing the safety and efficacy of regenerative medicine therapies.

NPJ Regenerative medicine·2018
Same author

Juvenile Nonclinical Safety Studies in Support of Pediatric Drug Development.

Methods in molecular biology (Clifton, N.J.)·2017
Same author

[Developmental and reproductive toxicology: interest and interpretation].

Therapie·2014
Same author

The teratology testing of food additives.

Methods in molecular biology (Clifton, N.J.)·2012
Same author

Developmental toxicity testing of vaccines.

Methods in molecular biology (Clifton, N.J.)·2012
Same author

The teratology testing of cosmetics.

Methods in molecular biology (Clifton, N.J.)·2012

Related Experiment Video

Updated: Jun 7, 2026

Evaluating Toxicity of Chemicals using a Zebrafish Vibration Startle Response Screening System
06:25

Evaluating Toxicity of Chemicals using a Zebrafish Vibration Startle Response Screening System

Published on: January 12, 2024

Preclinical evaluation of juvenile toxicity.

Paul C Barrow1, Stéphane Barbellion, Jeanne Stadler

  • 1Ricerca Biosciences, Les Oncins, Saint-Germain sur l'Arbresle, France. paul.barrow@mdsinc.com

Methods in Molecular Biology (Clifton, N.J.)
|October 26, 2010
PubMed
Summary

Pediatric assessments, including juvenile toxicity studies, are crucial for new drug approvals in North America and Europe. Early consultation with regulatory bodies like the FDA or EMEA ensures compliance and avoids delays.

More Related Videos

Rapid Evaluation of Toxicity of Chemical Compounds Using Zebrafish Embryos
07:49

Rapid Evaluation of Toxicity of Chemical Compounds Using Zebrafish Embryos

Published on: August 25, 2019

Small Molecule Screening and Toxicity Testing in Early-stage Zebrafish Larvae
02:52

Small Molecule Screening and Toxicity Testing in Early-stage Zebrafish Larvae

Published on: March 7, 2025

Related Experiment Videos

Last Updated: Jun 7, 2026

Evaluating Toxicity of Chemicals using a Zebrafish Vibration Startle Response Screening System
06:25

Evaluating Toxicity of Chemicals using a Zebrafish Vibration Startle Response Screening System

Published on: January 12, 2024

Rapid Evaluation of Toxicity of Chemical Compounds Using Zebrafish Embryos
07:49

Rapid Evaluation of Toxicity of Chemical Compounds Using Zebrafish Embryos

Published on: August 25, 2019

Small Molecule Screening and Toxicity Testing in Early-stage Zebrafish Larvae
02:52

Small Molecule Screening and Toxicity Testing in Early-stage Zebrafish Larvae

Published on: March 7, 2025

Area of Science:

  • Pharmacology and Toxicology
  • Regulatory Science

Background:

  • Pediatric assessments are mandatory for New Drug Applications (North America) and Marketing Authorization Applications (Europe).
  • Nonclinical juvenile toxicity studies are typically required as part of these pediatric assessments, unless a waiver is granted.
  • Protocols for these studies are developed in consultation with regulatory authorities such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMEA).

Purpose of the Study:

  • To highlight the regulatory requirement for pediatric assessments in drug development.
  • To emphasize the importance of juvenile toxicity studies in evaluating drug safety in pediatric populations.
  • To guide researchers on the necessary considerations and early engagement with regulatory bodies.

Main Methods:

  • Consultation with regulatory authorities (FDA/EMEA) to determine the necessity and design of juvenile toxicity studies.
  • Consideration of key factors including therapeutic use, pediatric patient age, treatment duration, and potential age- or species-specific pharmacokinetic and toxicity differences.
  • Development of study protocols based on these complex considerations.

Main Results:

  • Pediatric assessment and juvenile toxicity studies are integral to the drug approval process.
  • Early engagement with regulatory agencies is vital to confirm study requirements and prevent marketing authorization delays.
  • The design of juvenile studies necessitates a thorough evaluation of drug-specific and population-specific factors.

Conclusions:

  • Juvenile toxicity studies are a critical component of pediatric drug evaluation, requiring careful planning and regulatory consultation.
  • Proactive communication with the FDA or EMEA is essential for efficient drug development and approval.
  • Tailoring study designs to specific drug characteristics and pediatric populations ensures robust safety assessments.